Effects of AG490 and S3I‑201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL‑resistant prostate cancer cells in vitro

Gurbuz,Venhar; Konac,Ece; Varol,Nuray; Yilmaz,Akin; Gurocak,Serhat; Menevse,Sevda; Sozen,Sinan

doi:10.3892/ol.2014.1795

Effects of AG490 and S3I‑201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL‑resistant prostate cancer cells in vitro

Authors:
- Venhar Gurbuz
- Ece Konac
- Nuray Varol
- Akin Yilmaz
- Serhat Gurocak
- Sevda Menevse
- Sinan Sozen
View Affiliations

Affiliations: Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara 06500, Turkey, Department of Urology, Faculty of Medicine, Gazi University, Ankara 06500, Turkey
Published online on: January 14, 2014 https://doi.org/10.3892/ol.2014.1795
Pages: 755-763

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze the molecular mechanisms involved in blocking the signaling pathway and the effects of this on the progression of prostate cancer (CaP) cells in vitro. LNCaP human CaP cell line was stimulated with interleukin‑6 (IL‑6) in the presence/absence of Janus kinase (JAK) 2 (AG490), signal transducer and activator of transcription 3 [(STAT3) S3I‑201] inhibitors and tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL). Cytotoxic activity, the activation of phosphorylated (p)‑STAT3 protein, caspase (CASP) 3 activity at protein level, vascular endothelial growth factor (VEGF) A, VEGFC, vascular endothelial growth factor receptor 2, STAT3, matrix metalloproteinase-2, myeloid cell leukemia sequence 1 (MCL‑1), CASP8 and CASP9 messenger RNA (mRNA) levels were determined. Morphology and apoptosis were confirmed by DAPI staining and terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling (TUNEL) assay. IL‑6 rapidly induced the phosphorylation of STAT3 in a dose‑ and time‑dependent manner with a peak expression at 3 h at a concentration of 25 ng/ml. In addition, AG490 (50 µM) and S3I‑201 (300 µM) inhibited STAT3 activation. Western blotting results revealed that p‑STAT3 protein expression decreased significantly with AG490 and S3I‑201 treatment in LNCaP cells. AG490 and S3I‑201 induced the downregulation of VEGFA, MCL‑1 and STAT3 and the upregulation of CASP8 and CASP9 mRNA transcription levels. In addition, the inhibitors increased the level of CASP3 protein. Combinations of AG490‑ and S3I‑201‑TRAIL did not result in an increase in this effect. Parallel results were found by DAPI staining and TUNEL assay. To the best of our knowledge, this is the first study to investigate the possible clinical use of AG490 or S3I‑201, together with the reduced use of chemotherapeutic agents with high cytotoxicity, for their ability to exert an apoptotic effect, targeting the JAK/STAT3 pathway.

View Figures

View References

1	Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ and Troyer DA: Molecular pathology of prostate cancer. Cancer Biomark. 9:441–459. 2010.
2	Foley R, Hollywood D and Lawler M: Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer. 11:477–488. 2004. View Article : Google Scholar : PubMed/NCBI
3	Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
4	Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM and Edwards J: Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer. 97:378–383. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, et al: Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 15:4815–4822. 2009. View Article : Google Scholar : PubMed/NCBI
6	Germain D and Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI
7	Constantinescu SN, Girardot M and Pecquet C: Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 33:122–131. 2008. View Article : Google Scholar : PubMed/NCBI
8	Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
9	Agarwal C, Tyagi A, Kaur M and Agarwal R: Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis. 28:1463–1470. 2007. View Article : Google Scholar
10	Samanta AK, Lin H, Sun T, Kantarjian H and Arlinghaus RB: Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66:6468–6472. 2006. View Article : Google Scholar : PubMed/NCBI
11	Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, et al: Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 363:738–744. 2007. View Article : Google Scholar
12	Seo IA, Lee HK, Shin YK, Lee SH, Seo SY, Park JW and Park HT: Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130. Korean J Physiol Pharmacol. 13:131–138. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shodeinde AL and Barton BE: Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Oncol Targets Ther. 5:119–125. 2012.PubMed/NCBI
14	Flowers LO, Subramaniam PS and Johnson HM: A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene. 24:2114–2120. 2005. View Article : Google Scholar
15	Klampfer L: Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets. 6:107–121. 2006. View Article : Google Scholar : PubMed/NCBI
16	Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
17	Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
18	Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 13:1362–1366. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhang H, Zhang D, Luan X, Xie G and Pan X: Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res. 38:1673–1681. 2010. View Article : Google Scholar
20	Huang C, Yang G, Jiang T, Huang K, Cao J and Qiu Z: Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 29:512010. View Article : Google Scholar
21	Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM and Bromberg J: Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol. 27:4444–4453. 2007. View Article : Google Scholar : PubMed/NCBI
22	Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, et al: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 172:1717–1728. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, et al: Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 72:82–89. 2012. View Article : Google Scholar : PubMed/NCBI
24	Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al: IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene. 30:2345–2355. 2011. View Article : Google Scholar : PubMed/NCBI
25	Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 104:7391–7296. 2007. View Article : Google Scholar
26	Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI
27	Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, et al: A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 78:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
28	Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD and Lee WM: Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther. 7:1994–2003. 2008. View Article : Google Scholar : PubMed/NCBI
29	Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 24:5552–5560. 2005. View Article : Google Scholar : PubMed/NCBI
30	Cantarella G, Risuglia N, Dell’eva R, Lempereur L, Albini A, Pennisi G, et al: TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer. 94:1428–1435. 2006. View Article : Google Scholar : PubMed/NCBI
31	Liu H, Chen A, Guo F and Yuan L: A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett. 295:27–37. 2010. View Article : Google Scholar : PubMed/NCBI
32	Bhattacharya S, Ray RM and Johnson LR: STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 392:335–344. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, et al: Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 9:92010. View Article : Google Scholar
34	Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, et al: Effective targeting of prostate cancer by lymphocytes redirected by a PSMA×CD3 bispecific single-chain diabody. Prostate. 71:588–596. 2011.PubMed/NCBI
35	Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, Moore RG and Singh RK: 7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells. Gynecol Oncol. 126:252–258. 2012. View Article : Google Scholar
36	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar
37	Huang C, Huang R, Chang W, Jiang T, Huang K, Cao J, et al: The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma. 59:52–61. 2012. View Article : Google Scholar
38	Liu X, He Z, Li CH, Huang G, Ding C and Liu H: Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res. 18:17–23. 2012. View Article : Google Scholar : PubMed/NCBI
39	Wang T, Yan XB, Zhao JJ, Ye J, Jiang ZF, Wu DR, et al: Gene associated with retinoid-interferon-induced mortality-19 suppresses growth of lung adenocarcinoma tumor in vitro and in vivo. Lung Cancer. 72:287–293. 2011. View Article : Google Scholar
40	Lavecchia A, Di Giovanni C and Novellino E: STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem. 18:2359–2375. 2011. View Article : Google Scholar : PubMed/NCBI
41	Santer FR, Malinowska K, Culig Z and Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 17:241–253. 2010. View Article : Google Scholar
42	Yu JH, Kim KH and Kim H: Suppression of IL-1beta expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochem Pharmacol. 72:1555–1562. 2006. View Article : Google Scholar : PubMed/NCBI
43	Lanuti P, Bertagnolo V, Pierdomenico L, Bascelli A, Santavenere E, Alinari L, et al: Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Res. 19:1079–1089. 2009. View Article : Google Scholar
44	Shu M, Zhou Y, Zhu W, Wu S, Zheng X and Yan G: Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. Mol Oncol. 5:265–272. 2011. View Article : Google Scholar
45	Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, et al: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 28:961–972. 2009. View Article : Google Scholar : PubMed/NCBI
46	Chen W, Shen X, Xia X, Xu G, Ma T, Bai X, et al: NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 32:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
47	Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 12:39–50. 2010.
48	Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 107:351–362. 2001. View Article : Google Scholar
49	Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, et al: Vascular endothelial growth factor contributes to prostate cancer- mediated osteoblastic activity. Cancer Res. 65:10921–10929. 2005. View Article : Google Scholar
50	Huang W, Yu LF, Zhong J, Wu W, Zhu JY, Jiang FX and Wu YL: Stat3 is involved in angiotensin II-induced expression of MMP2 in gastric cancer cells. Dig Dis Sci. 54:2056–2062. 2009. View Article : Google Scholar : PubMed/NCBI
51	Kang J, Bu J, Hao Y and Chen F: Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis. 8:274–279. 2005. View Article : Google Scholar : PubMed/NCBI
52	Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 276:10767–10774. 2001. View Article : Google Scholar : PubMed/NCBI
53	Horndasch M and Culig Z: SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate. 71:1357–1366. 2011.